


IAW

serial No.:	10/695,382			Examiner: Unassigned			
Filed:	28 October 2003			Docket No.: 180.0005 0102 Confirmation No.: 5299			
Title:	NOVEL GnRH AND PHARMACEUTICA		ANTITUMOUR EF	OUR EFFECTS AND			
Mail Stop Amen Commissioner fo P.O. Box 1450 Alexandria, VA	or Patents	· · · · · · · · · · · · · · · · · · ·					
X Small X An item A Petiti X A Supp and cop A check A certif		ime for _ month(s) Disclosure Stateme cited on the 1449 f representing	and a check in the nt (2 pgs); copies of filed, the	amount of \$_ for the found of applications; 1 the right of priority of	pplication. the required fee. 449 form (1 pg); Which is claimed		
	Fee Calc	ulation for Claims	Pending After An	nendment			
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required		
Total Claims				x \$25 =			
Independent Claims				x \$100 =			
One or	More New Multiple	Dependent Claims I	Presented? If Yes, A	Add \$180 Here→			
	Total Additional Claim Fees Required						
Triplicate copie CERTIFICATE paper(s), as descenvelope address 1450, on this	ASCH & GEBHARD	\$1.8: The undersige being deposited in endment Commiss. (1) (2006)	eredit overpaymen ned hereby certifies the United States F	s that this Transmitt Postal Service, as fir O. Box 1450, Alex Mueting	al Letter and the rst class mail, in an		

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.8)

کے





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Sandor LOVAS et al.)	Group Art Unit: 1653		
Serial No.: Confirm. No.:	•))	Examiner:	Unassigned	
Filed:	28 October 2003)			
For:	NOVEL GnRH ANALOGUE PHARMACEUTICAL COME				

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed are copies of two documents cited in a Japanese Office Action which are not already of record in the present matter. Enclosed for the Examiner's information is a copy of the English translated Japanese Office Action and copies of documents which Applicants bring to the Examiner's attention as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of MPEP §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Supplemental Information Disclosure Statement

Applicant(s):

Sandor LOVAS et al.

Serial No.:

10/695,382

For:

NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL

COMPOSITIONS THEREOF

It is believed that no fee is due, as this Supplemental Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

CERTIFICATION

Under 1.704(d), the undersigned attorney hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>5</u> day of <u>May</u>, 2006.

Signature:

Printed Name: 1

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone (612)305-1220

Facsimile (612)305-1228

Customer Number 26813

Ann M. Mueting

Reg. No. 33,977

Direct Dial (612)305-1217

INFORMATION
DISCLOSURE
STACEMENT
MAY 0 8 2006 8
TRADE MAN

Atty. Docket No.: 180.0005 0102	Serial No.: 10/695,382
Applicant(s): Sandor LOVAS et al.	Confirmation No.: 5299
Application Filing Date: 28 October 2002	Group: 1653
Information Disclosure Statement mailed:	<u>5</u> May 2006

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	None			•		

FOREIGN PATENT DOCUMENTS

Examiner	Сору	Document Number	Date	Country	Class	Subclass		lation
Initial	Enclosed						Yes	No
:	X	505210/1991	11/14/1991	Japan (*English Abstract)	:		X*	
	X	JP Office Action Mail No. 064236	02/21/2006	Japan			X	
	X	WO 93/14142	07/22/1993	PCT / WO				

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Document Description

EXAMINER	Date Considered	
APP	A LANGUAGO DE LA	_

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.